111 related articles for article (PubMed ID: 12839693)
1. [Recombinant human interleukin-11 in the prevention of chemotherapy-induced thrombocytopenia].
Chu DT; Xu BH; Song ST; Mao XH; Jiao SC; Zhang AL
Zhonghua Zhong Liu Za Zhi; 2003 May; 25(3):272-4. PubMed ID: 12839693
[TBL] [Abstract][Full Text] [Related]
2. [Clinical study of rhIL-11 for prevention and treatment of chemotherapy-induced thrombocytopenia].
Sun XF; Guan ZZ; Huang H; Zhou QH; Yi C; Zhang LJ; Zhu J; Li R; Zhou J; Zhang M; Guo Y
Ai Zheng; 2002 Aug; 21(8):892-5. PubMed ID: 12478901
[TBL] [Abstract][Full Text] [Related]
3. [Phase II clinical trial on China manufactured recombinant human interleukin-11 derivative in the prevention and treatment of chemotherapy-induced thrombocytopenia].
Wang XY; Feng FY; Song ST; Wang HQ; Zhang MH; Liu J; Liu XY; Xu LG; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2005 Jun; 27(6):373-6. PubMed ID: 16117903
[TBL] [Abstract][Full Text] [Related]
4. [Effectiveness and safety of recombinant human interleukin-11 in the treatment of chemotherapy-induced thrombocytopenia].
Lei W; Liang J; Chen WG; Ma XZ; Xu M; Du LL
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):542-4. PubMed ID: 17147124
[TBL] [Abstract][Full Text] [Related]
5. [A multi-center clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor].
Bai CM; Xu GX; Zhao YQ; Han SM; Shan YD
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug; 26(4):437-41. PubMed ID: 15379272
[TBL] [Abstract][Full Text] [Related]
6. The clinical development of recombinant human interleukin 11 (NEUMEGA rhIL-11 growth factor).
Kaye JA
Stem Cells; 1996; 14 Suppl 1():256-60. PubMed ID: 11012229
[TBL] [Abstract][Full Text] [Related]
7. [Effectiveness and safety of rhIL-11 in the treatment of chemotherapy-induced thrombocytopenia].
Li L; Xu CG; Wang XW; Guo QS; Sun YH; Sun LM
Zhonghua Zhong Liu Za Zhi; 2005 Jun; 27(6):377-9. PubMed ID: 16117904
[TBL] [Abstract][Full Text] [Related]
8. [The clinical study of recombinant human thrombopoietin in the treatment of chemotherapy-induced severe thrombocytopenia].
Bai CM; Zou XY; Zhao YQ; Han SM; Shan YD;
Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(5):397-400. PubMed ID: 15061993
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy.
Cantor SB; Elting LS; Hudson DV; Rubenstein EB
Cancer; 2003 Jun; 97(12):3099-106. PubMed ID: 12784347
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a southwest oncology group study.
Rinehart J; Margolin KA; Triozzi P; Hersh E; Campion M; Resta D; Levitt D
Clin Cancer Res; 1995 Oct; 1(10):1139-44. PubMed ID: 9815905
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human interleukin-11 improved carboplatin-induced thrombocytopenia without affecting antitumor activities in mice bearing Lewis lung carcinoma cells.
Saitoh M; Taguchi K; Momose K; Suga K; Yamazaki N; Ono C; Suzuki T; Takeuchi O; Yasuda S; Miyata K
Cancer Chemother Pharmacol; 2002 Feb; 49(2):161-6. PubMed ID: 11862431
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.
Cairo MS; Davenport V; Bessmertny O; Goldman SC; Berg SL; Kreissman SG; Laver J; Shen V; Secola R; van de Ven C; Reaman GH
Br J Haematol; 2005 Jan; 128(1):49-58. PubMed ID: 15606549
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of rhIL-11.
Reynolds CH
Oncology (Williston Park); 2000 Sep; 14(9 Suppl 8):32-40. PubMed ID: 11033836
[TBL] [Abstract][Full Text] [Related]
14. FDA licensure of NEUMEGA to prevent severe chemotherapy-induced thrombocytopenia.
Kaye JA
Stem Cells; 1998; 16 Suppl 2():207-23. PubMed ID: 11012193
[TBL] [Abstract][Full Text] [Related]
15. [Value of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor].
Dai XF; Yu J; Liu L; Wu G
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):623-5. PubMed ID: 19102944
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human interleukin-11 improves thrombocytopenia in patients with cirrhosis.
Ghalib R; Levine C; Hassan M; McClelland T; Goss J; Stribling R; Seu P; Patt YZ
Hepatology; 2003 May; 37(5):1165-71. PubMed ID: 12717398
[TBL] [Abstract][Full Text] [Related]
17. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin.
Isaacs C; Robert NJ; Bailey FA; Schuster MW; Overmoyer B; Graham M; Cai B; Beach KJ; Loewy JW; Kaye JA
J Clin Oncol; 1997 Nov; 15(11):3368-77. PubMed ID: 9363868
[TBL] [Abstract][Full Text] [Related]
18. [The efficacy and mechanism of rhIL-11 in the management of chemotherapy-induced thrombocytopenia in acute leukemia].
Cui XL; Wang L; Gao J; Qin P; Shi Y; Peng J; Hou M
Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):345-7. PubMed ID: 16185478
[TBL] [Abstract][Full Text] [Related]
19. [Efficiency, safety and tolerability of recombinant human interleukin-3 (rhIL-3) as supportive therapy accompanying dose-intensive carboplatin containing chemotherapy in ovarian cancer with special regard to thrombocytopenia].
Meden H; Fock M; Krauss T; Kuhn W
Zentralbl Gynakol; 1999; 121(8):375-83. PubMed ID: 10486880
[TBL] [Abstract][Full Text] [Related]
20. [Effect of recombinant human interleukin 11 on the platelet after hematopoietic stem cell transplantation in patients with leukemia].
Xu YJ; Chen FP; Li XL; Zhao XL; He Q
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Jun; 32(3):433-6. PubMed ID: 17611320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
